Production Capacity and Market Demand - The company plans to increase production capacity by 800 tons of BA (Dexamethasone) and 200 tons of Progesterone, responding to the growing market demand for steroid hormone drugs [9]. - The company is actively preparing to expand its market presence to ensure the successful absorption of new production capacity [9]. - The domestic market for steroid drugs is experiencing a continuous demand increase, with international sales growing at an annual rate of 10%-15%, making steroid drugs the second largest category after antibiotics [45]. - The steroid hormone drug market is experiencing continuous growth, with global sales exceeding $150 billion in 2020, indicating strong demand for steroid hormone intermediates and raw materials [35]. - The company is positioned to become a global production center for steroid hormone raw materials and intermediates, given its current production capacity [35]. Financial Performance - The company's operating revenue for 2021 was ¥590,885,338.44, representing a 26.23% increase compared to ¥468,117,263.96 in 2020 [25]. - The net profit attributable to shareholders for 2021 was ¥78,330,635.77, a 46.99% increase from ¥53,288,521.48 in 2020 [25]. - The net cash flow from operating activities reached ¥58,004,300.45, marking a significant increase of 330.46% from ¥13,474,987.99 in 2020 [25]. - The total assets at the end of 2021 amounted to ¥1,211,243,283.36, a 50.57% increase from ¥804,426,535.29 at the end of 2020 [25]. - The company reported a basic earnings per share of ¥0.74 for 2021, up 19.35% from ¥0.62 in 2020 [25]. Research and Development - R&D investment accounted for 6.28% of total revenue, with a stable core technology team in place [56]. - The company has established three new R&D centers to enhance its research capabilities and focus on high-end steroid drug development [57]. - The company completed the R&D of several new products, including the high-end progesterone intermediate and the new process for progesterone, which are expected to enhance product lines and competitiveness [69]. - The company aims to enhance its research and development capabilities, with a focus on new products and processes, leveraging its R&D centers in Hangzhou and Wuhan [96]. - Research and development investments increased by 25% in 2021, focusing on innovative drug formulations and delivery systems [181]. Environmental Management - The company emphasizes environmental protection and has established a comprehensive environmental management system, ensuring compliance with national standards and reducing pollution [8]. - The company acknowledges the increasing environmental governance costs due to stricter regulations and is prepared to invest in compliance measures [7]. - The company has implemented a wastewater treatment process that includes acid-base pre-treatment and a series of treatment stages, ensuring compliance with environmental standards [163]. - The company has established a strict hazardous waste management system, ensuring compliance with regulations and proper disposal of hazardous materials [167]. - The company has not faced any environmental pollution incidents or regulatory penalties during the reporting period, demonstrating compliance with environmental laws [168]. Corporate Governance - The company maintains complete independence in operations, assets, personnel, finance, and institutions from its controlling shareholders [116]. - The company has a fully independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders [120]. - The company has a well-established corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team [121]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted [115]. - The company has established a dedicated "Investor Relations" section on its official website to maintain good communication with investors [115]. Employee Management - The company has established a comprehensive salary system and incentive mechanism to ensure employee interests are protected [146]. - The company emphasizes employee training, with a structured training system that includes both internal and external training programs [147]. - The total number of employees at the end of the reporting period was 481, with 151 in the parent company and 330 in major subsidiaries [145]. - The company has a focus on research and development, providing project incentive bonuses to employees based on their contributions to technological improvements [146]. - The company has a strict internal control system in place, with no significant deficiencies identified in financial reporting during the reporting period [151]. Strategic Plans and Future Outlook - The company plans to officially launch its fundraising projects by the end of 2022, including the completion of construction for the joint project with Huahai [92]. - The company aims to strengthen its market position in the hormone raw material and intermediate sectors, targeting a top-tier position in the next five years [93]. - The company plans to optimize its market layout by consolidating existing advantages and developing new emerging areas [94]. - The company expects a revenue growth guidance of 10% to 12% for the upcoming fiscal year, driven by new product launches and market expansion strategies [182]. - The company provided a future outlook projecting a revenue growth of 10% for 2022, aiming for 1.32 billion yuan [179].

Financial Performance - The company's revenue for Q3 2021 reached ¥143,270,966.07, representing a 22.01% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 was ¥13,021,687.46, a 3.28% increase year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 14.59% to ¥9,423,092.27 in Q3 2021[2]. - Total operating revenue for Q3 2021 reached CNY 445,950,409.88, a 39.5% increase from CNY 319,492,200.40 in the same period last year[20]. - Net profit attributable to the parent company was CNY 54,065,347.95, representing a 72.8% increase compared to CNY 31,290,293.73 in Q3 2020[21]. - Operating profit for the period was CNY 52,707,982.29, an increase of 57.3% from CNY 33,492,300.59 in the previous year[20]. - The total profit for the period was CNY 60,475,188.00, up 68.9% from CNY 35,772,929.41 in Q3 2020[20]. - Earnings per share for the quarter were CNY 0.53, compared to CNY 0.36 in the same quarter last year, marking a 47.2% increase[21]. Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,055,432,040.81, reflecting a 31.20% increase from the end of the previous year[2]. - The company's current assets reached CNY 750,247,277.45, up from CNY 579,642,443.60 at the end of 2020, indicating an increase of about 29.4%[15][17]. - The cash and cash equivalents increased significantly to CNY 122,819,652.53 from CNY 28,963,697.71, marking a growth of approximately 324.5%[15][17]. - Accounts receivable rose to CNY 247,424,461.89, compared to CNY 207,182,890.78 at the end of 2020, reflecting an increase of about 19.4%[15][17]. - Inventory levels increased to CNY 261,923,586.30 from CNY 200,739,033.05, which is an increase of approximately 30.5%[15][17]. - The total liabilities of the company were CNY 267,576,085.42, slightly up from CNY 264,579,247.03 at the end of 2020, showing a marginal increase of about 1.0%[17]. - The total equity attributable to shareholders increased to CNY 782,787,729.54 from CNY 534,540,315.19, representing a growth of approximately 46.4%[17]. Cash Flow and Investments - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥1,227,234.45 for the first nine months, although it showed a decline of 91.28% compared to the previous year[2]. - Cash flow from operating activities generated a net amount of CNY 1,227,234.45, a significant decrease from CNY 14,073,404.57 in the same quarter last year[24]. - The company raised CNY 210,160,000.00 from investment activities, a significant increase from CNY 5,400,017.80 in the previous year[24]. Research and Development - Research and development expenses for the first nine months of 2021 rose by 125.20% to ¥24,512,055.83, indicating increased investment in innovation[7]. - Research and development expenses increased to CNY 24,512,055.83, compared to CNY 10,884,586.20 in the same period last year, reflecting a 125.5% rise[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,789, indicating a broad base of investor support[10]. - The company reported a total of 87,773,991 shares under lock-up agreements, with various shareholders holding significant amounts[12][14]. - The company has committed to releasing certain locked shares on specified dates, with the largest block being 36,567,000 shares held by Xi Zuobin, set to be released on April 9, 2024[12][14]. Government Support - The company received government subsidies amounting to ¥4,136,095.05 in Q3 2021, contributing to its financial performance[5]. Financial Stability - The company has maintained a stable financial position with a current ratio indicating sufficient liquidity to meet short-term obligations[15][17].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million yuan for the first half of 2021, representing a year-on-year growth of 20%[19]. - The company's operating revenue for the reporting period was CNY 302,679,443.73, representing a 49.79% increase compared to CNY 202,068,402.69 in the same period last year[25]. - The net profit attributable to shareholders was CNY 41,043,660.49, a significant increase of 119.70% from CNY 18,682,036.96 year-on-year[25]. - The net profit after deducting non-recurring gains and losses was CNY 34,953,945.77, reflecting a 119.96% increase compared to CNY 15,891,199.48 in the previous year[25]. - The company's total assets at the end of the reporting period reached CNY 1,044,913,146.49, up 29.90% from CNY 804,426,535.29 at the end of the previous year[25]. - The basic earnings per share rose to CNY 0.43, a 95.45% increase from CNY 0.22 in the same period last year[25]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2021, representing a year-on-year increase of 15%[96]. - The company reported a net profit of 35,932,359.10 CNY from its subsidiary, Hubei Joint Biological Technology Co., Ltd., contributing significantly to its overall performance[68]. Market Expansion and Strategy - The company has set a future outlook with a revenue target of 1 billion yuan for the full year 2021, indicating a projected growth rate of 25%[19]. - The company plans to expand its market presence by entering three new provinces, aiming for a 10% market share in these regions within the next year[19]. - The company is actively pursuing strategic acquisitions, with a target to acquire a complementary business by the end of 2021 to enhance its product portfolio[19]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2022[96]. - A strategic acquisition of a local competitor is anticipated to enhance the company's distribution network and increase operational efficiency[96]. Research and Development - The company has invested 50 million yuan in R&D for new technologies, focusing on improving production efficiency and product quality[19]. - Research and development investment reached ¥12,768,860.22, marking a 99.00% increase as R&D projects returned to normal operations[48]. - The company has formed independent research teams focusing on the development of new products and processes, particularly in the areas of steroid anti-tumor drugs and hypertension treatments[39]. - Future product development will focus on innovative drug formulations, with an investment of 100 million RMB allocated for the next fiscal year[96]. Financial Management and Investments - The company has implemented cost-reduction strategies, resulting in a 5% decrease in production costs, enhancing overall profitability[19]. - The company reported a net cash flow from operating activities of CNY 5,929,756.84, a decrease of 67.19% compared to CNY 18,073,361.48 in the previous year[25]. - The company reported a significant increase in cash and cash equivalents, totaling ¥149,738,375.24, a rise of 5,072.67% compared to the previous year[48]. - The company raised a total of 238,960,000 CNY from the issuance of 29,000,000 shares at a price of 8.24 CNY/share[126]. - The total cash and cash equivalents at the end of the period reached 150,393,490.91 CNY, up from 15,461,971.00 CNY in the previous period, reflecting a net increase of 145,879,449.18 CNY[164]. Environmental and Social Responsibility - Environmental management initiatives have been strengthened, with an investment of 10 million yuan in new equipment to ensure compliance with stricter regulations[19]. - The company has actively participated in social responsibility initiatives, including infrastructure development and employment support in local communities[89]. - The company has provided support for 18 impoverished households, including housing repairs and employment opportunities[90]. - The company has maintained compliance with environmental regulations and has not faced any pollution incidents[88]. Corporate Governance and Compliance - The company has not declared any cash dividends for the year, opting to reinvest profits into growth initiatives[10]. - The company has not engaged in any investor communication activities during the reporting period[78]. - The company has not made any changes to its board of directors or senior management during the reporting period[82]. - The company has not implemented any employee incentive plans during the reporting period[84]. - The company has committed to ensuring the accuracy and completeness of its IPO prospectus, taking legal responsibility for any misstatements[122]. Shareholder Information - The total share capital increased from 86,277,000 shares to 115,277,000 shares after the public offering in April 2021[123]. - The largest shareholder, Xi Zubin, holds 31.72% of the shares, totaling 36,567,000 shares[129]. - The company has a total of 87,773,991 shares under lock-up agreements due to pre-IPO commitments[125]. - The company will publicly apologize and correct any unfulfilled commitments in accordance with regulatory requirements[93].

Financial Performance - The company's operating revenue for Q1 2021 was ¥141,827,415.71, representing a 284.06% increase compared to ¥36,928,882.41 in the same period last year[7] - Net profit attributable to shareholders was ¥15,277,393.73, a significant increase of 793.48% from a loss of ¥2,203,004.31 in the previous year[7] - Basic earnings per share rose to ¥0.18, up 700.00% from a loss of ¥0.03 per share in the previous year[7] - The company achieved operating revenue of CNY 141.83 million in Q1 2021, a year-on-year increase of 284.06% due to recovery from the pandemic's impact in the previous year[15] - The net profit attributable to shareholders reached CNY 15.28 million, compared to a loss of CNY 2.20 million in the same period last year, driven by normalized sales and procurement logistics[17] - The company reported a total profit of CNY 18,107,233.71, compared to a total loss of CNY 2,203,004.31 in the previous year[39] - The company reported an operating profit of CNY 17,650,222.77, compared to an operating loss of CNY 2,179,409.47 in the previous year[39] Cash Flow - The net cash flow from operating activities improved to ¥13,908,393.23, compared to a negative cash flow of ¥17,820,932.10 in the same period last year, marking a 178.05% increase[7] - The cash inflow from operating activities amounted to CNY 127,979,909.60, significantly up from CNY 14,271,658.82 in the previous period[46] - The net cash flow from operating activities was CNY 13,908,393.23, recovering from a negative CNY -17,820,932.10 in the prior year[47] - Cash inflow from financing activities was CNY 59,267,222.22, an increase from CNY 50,000,000.00 in the previous period[48] - The net cash flow from financing activities was CNY 834,313.35, down from CNY 13,377,459.58 in the prior year[48] - The company experienced a net decrease in cash and cash equivalents of CNY 12,475,078.01, contrasting with a decrease of CNY -7,980,886.65 in the previous year[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥826,762,043.44, reflecting a 2.78% increase from ¥804,426,535.29 at the end of the previous year[7] - The company's current assets totaled CNY 604,826,734.34, up from CNY 579,642,443.60 at the end of 2020, indicating an increase of about 4.27%[29] - Total liabilities rose to CNY 272,052,008.25 from CNY 264,579,247.03, indicating an increase of approximately 2.8%[31] - The company's equity attributable to shareholders increased to CNY 549,334,993.07 from CNY 534,540,315.19, reflecting a growth of about 2.76%[32] Research and Development - Research and development expenses increased by 196.22% to CNY 6.58 million, reflecting a return to normal R&D activities after pandemic-related restrictions[15] - Research and development expenses increased to CNY 6,580,076.26 from CNY 2,221,362.76, reflecting the company's commitment to innovation[38] Shareholder Information - The top shareholder, Xi Zubin, holds 42.38% of the shares, totaling 36,567,000 shares[11] - The company reported no changes in the number of shares due to new issuance or other reasons affecting equity[7] Government Support - The company received government subsidies amounting to ¥915,351.97 during the reporting period[8] Operational Developments - The company signed a significant order with its top five suppliers, with procurement amount increasing by 386.84% year-on-year, indicating a recovery in supply chain operations[17] - The company initiated a top-level design for its ERP system to enhance operational efficiency and standardization in response to its expanding scale[20] - The company plans to expand its product and technology offerings in the steroid drug sector, including a joint venture to produce 300 tons of acetate and 200 tons of 17α-hydroxyprogesterone annually[20] Tax and Fees - The company reported a 379.80% increase in business tax and additional fees, attributed to the recovery of revenue following the pandemic[15] Other Financial Information - Total operating costs amounted to CNY 123,053,088.90, compared to CNY 39,411,549.29 in the previous year, indicating a rise in costs associated with increased revenue[38] - Other income for the quarter was CNY 439,839.26, an increase from CNY 303,257.41 in the same period last year[38] - The total comprehensive income for the first quarter was CNY 263,665.07, a decrease from CNY -651,666.73 in the previous period[44] - Basic and diluted earnings per share were both CNY 0.0031, compared to CNY -0.0076 in the same period last year[44] Audit Information - The company has not undergone an audit for the first quarter report[53]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan in 2020, representing a year-on-year growth of 15%[1]. - The company's operating revenue for 2020 was CNY 468,117,263.96, representing a 0.71% increase compared to CNY 464,801,920.27 in 2019[21]. - The company reported a total operating revenue of RMB 468,117,263.96 in 2020, representing a year-on-year increase of 0.71% compared to RMB 464,801,920.27 in 2019[47]. - The company reported a revenue of 1.5 billion CNY for the fiscal year 2020, representing a year-over-year growth of 12%[96]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2020, representing a year-over-year growth of 12%[101]. - The net profit attributable to shareholders decreased by 27.00% to CNY 53,288,521.48 from CNY 72,996,358.19 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 46,137,480.66, down 20.70% from CNY 58,177,550.26 in 2019[21]. - The net profit attributable to shareholders was 53.29 million yuan, a decrease of 27% year-on-year[41]. - The company reported a net profit available for distribution to ordinary shareholders of CNY 197,358,601.28, with no cash dividends distributed during the reporting period, resulting in a cash dividend ratio of 0.00%[84]. - The company has not conducted any cash dividend distribution in the past three years, focusing instead on increasing R&D investment and expanding production capacity[86]. Research and Development - The company plans to invest 200 million yuan in R&D for new product development and technological advancements in the next fiscal year[1]. - Research and development investments have increased by 30%, totaling 150 million CNY, to enhance product pipeline and technology advancements[94]. - The company’s R&D investment accounted for 4.62% of total revenue in 2020, with a stable core technology team and a focus on environmental, health, and safety management[44]. - The company has ongoing R&D projects aimed at improving production processes for various hormone intermediates and expanding its product offerings[59]. - The company has maintained a stable core technology team and continuous R&D investment, focusing on biotechnological advancements and green synthesis techniques[37]. - Research and development efforts have led to the introduction of three new pharmaceutical products, expected to contribute an additional 300 million CNY in revenue[99]. - The company is exploring potential acquisitions to bolster its portfolio, with a budget of 500 million CNY allocated for this purpose[89]. Market Expansion - The company is expanding its market presence, targeting a 30% increase in sales in the Southeast Asian market over the next two years[1]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next year through strategic partnerships[93]. - The company plans to enhance its distribution network, which is expected to reduce delivery times by 20%[91]. - The company aims to enhance its online sales channel, targeting a 30% increase in e-commerce revenue by the end of the next fiscal year[99]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[100]. Operational Efficiency - The gross profit margin improved to 45%, up from 40% in the previous year, indicating enhanced operational efficiency[1]. - The company aims to enhance its production capacity by accelerating the construction of fundraising projects, with a focus on the production of steroid raw materials[80]. - Investment in technology upgrades is expected to improve operational efficiency by 25% over the next year[98]. - The company has set a target to reduce operational costs by 5% through efficiency improvements in the supply chain[102]. Environmental Management - Environmental management investments increased by 10% to ensure compliance with stricter regulations[1]. - The company has made significant investments in environmental protection measures to mitigate potential risks associated with waste management[81]. - The company has not experienced any environmental accidents during the reporting period and is committed to enhancing its EHS management system to comply with national environmental standards[81]. - The company has established a strict hazardous waste management system, ensuring compliance with regulations and regular third-party audits[134]. - The company has committed to regular monitoring of pollutant emissions through third-party assessments[136]. Shareholder Information - The total number of shares is 86,277,000, with 100% being limited sale condition shares[141]. - Domestic natural persons hold 64.95% of the shares, amounting to 56,037,400 shares[141]. - The largest shareholder, Xi Zuobin, holds 42.38% of the shares, totaling 36,567,000 shares[144]. - The second-largest shareholder, Li Minglei, holds 17.82% of the shares, totaling 15,371,000 shares[144]. - The company has not conducted any repurchase transactions during the reporting period[145]. Management and Governance - The company has a strong management team with members holding significant experience in finance, law, and pharmaceutical sectors, enhancing its operational capabilities[161]. - The company has established a board of independent directors, including Xia Chengtai and Yang Jian, to ensure governance and strategic oversight[161]. - The total remuneration for the board of directors, supervisors, and senior management in 2020 amounted to CNY 1.603 million, with 12 individuals receiving payments[165]. - The performance evaluation system for senior management is linked to both individual performance and overall company performance, promoting alignment with corporate goals[189]. - The company reported no significant internal control deficiencies during the reporting period, indicating a robust internal control environment[190]. Customer and Supplier Relationships - The company has established long-term stable relationships with upstream suppliers to ensure a smooth supply chain for raw materials[30]. - The company’s major customers accounted for 41.07% of total annual sales, with no sales to related parties[54]. - The top five customers contributed a total sales amount of ¥192,255,676.25, accounting for 41.07% of the annual total sales[55]. - The top five suppliers had a total procurement amount of ¥121,888,383.60, representing 44.18% of the annual total procurement[56]. Social Responsibility - The company reported a donation of 200,000 yuan and 34.35 tons of medical disinfectant alcohol to local governments in Xiangyang and Shiyan during the pandemic[129]. - The company donated 5,000 pairs of protective gloves and 500 goggles to hospitals in Xiangyang and Yicheng through overseas sales channels[129]. - The company has been recognized as a key enterprise for epidemic prevention and control, producing significant quantities of disinfectants during the pandemic[42].